LUPRON IS FIRST ABBOTT-TAKEDA PRODUCT TO REACH U.S. MARKET; FDA APPROVES SYNTHETIC LHRH ANALOG; WAS TREATED AS 1-A BREAKTHROUGH FOR PROSTATE CANCER